Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines.
Feature|Articles|August 19, 2026
From Pilot to Profit: How Pharma Leaders Are Scaling AI Across the Drug Lifecycle
Author(s)Mohd Haque
Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the leaders from the rest.
Advertisement
Advertisement
Pharma companies have spent the last several years testing AI across discovery, development, manufacturing, and commercialization. With the potential to create $60 billion to $110 billion annual economic value across the industry, AI has become too important to remain stuck in pilot mode. Today, only a small group of companies is starting to turn AI into measurable business gains, with Boston Consulting Group finding that AI-first biopharma companies are reporting 5 percent to 15 percent revenue uplift.
Related to this article
Clinical data harmonization is the real bottleneck standing between life sciences companies and AI's transformative potential.
Regeneron and Sanofi are expanding their two-decade antibody alliance to co-develop four new long-acting immunology antibodies in a deal worth up to $8 billion.
Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.
CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.
MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.
Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.
Advertisement
Advertisement